Cargando…

Zoledronic acid for prevention of bone loss in patients receiving bariatric surgery

PURPOSE: Bariatric surgery is an effective treatment for severe obesity but causes substantial bone loss and increased risk of fractures. To date, there have been no studies examining whether pharmacologic treatments can prevent bone loss after bariatric surgery. We performed an exploratory study to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Yi, Côté, Maya M., Cheney, Michael C., Lindeman, Katherine G., Rushin, Claire C., Hutter, Matthew M., Yu, Elaine W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8005765/ https://www.ncbi.nlm.nih.gov/pubmed/33816718 http://dx.doi.org/10.1016/j.bonr.2021.100760

Ejemplares similares

SAT-518 Long-term Impact of Gastric Bypass on Bone Density >10 years after Bariatric Surgery: Exceeding Physiologic Expectations
por: Rushin, Claire, et al.
Publicado: (2019)

Zoledronic Acid for prevention of bone and muscle loss after BAriatric Surgery (ZABAS)-a study protocol for a randomized controlled trial
por: Gam, Søren, et al.
Publicado: (2022)

OR13-04 Risk Of Wrist Fracture In Gastric Bypass Compared To Gastric Banding As Estimated By The Load-To-Strength Ratio
por: Jung, Grace H, et al.
Publicado: (2023)

Preventive effect of zoledronic acid on aromatase inhibitor-associated bone loss for postmenopausal breast cancer patients receiving adjuvant letrozole
por: Sun, Shengliang, et al.
Publicado: (2016)

Bone Response to Weight Loss Following Bariatric Surgery
por: Mele, Chiara, et al.
Publicado: (2022)

Protocol for a pilot randomised controlled trial of zoledronic acid to prevent bone loss following sleeve gastrectomy surgery
por: Flores, Laura E, et al.
Publicado: (2021)

OR13-02 Treatment with Zoledronic Acid Subsequent to Denosumab Cannot Fully Prevent Bone Loss
por: Sølling, Anne Sophie K, et al.
Publicado: (2020)

Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study
por: Tutaworn, Teerapat, et al.
Publicado: (2023)

THU449 An Unexpected Case Of Cutaneous Leukocytoclastic Vasculitis Following Zoledronic Acid Infusion
por: Zahedi, Bita, et al.
Publicado: (2023)

A combination of methotrexate and zoledronic acid prevents bone erosions and systemic bone mass loss in collagen induced arthritis
por: Le Goff, Benoit, et al.
Publicado: (2009)

Insufficient Mitigation of Bone Loss by Zoledronic Acid after Treatment with Denosumab
por: Park, Jung-Wee
Publicado: (2021)

Effect of Acetazolamide and Zoledronate on Simulated High Altitude-Induced Bone Loss
por: Brent, Mikkel Bo, et al.
Publicado: (2022)

Bone Health after Bariatric Surgery: Consequences, Prevention, and Treatment
por: Sayadi Shahraki, Masood, et al.
Publicado: (2022)

Preoperative zoledronic acid therapy prevent hungry bone syndrome in patients with primary hyperparathyroidism
por: Mayilvaganan, Sabaretnam, et al.
Publicado: (2017)

The effect of zoledronate during bone healing
por: Matos, Marcos Almeida, et al.
Publicado: (2010)

Zoledronic acid protects from local and systemic bone loss in TNF-mediated arthritis
por: Zwerina, J, et al.
Publicado: (2004)

Zoledronic Acid after Treatment with Denosumab is Associated with Bone Loss within 1 Year
por: Kadaru, Tarun, et al.
Publicado: (2021)

Bone turnover after bariatric surgery
por: Melo, Thalita Lima, et al.
Publicado: (2017)

Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women
por: Lambrinoudaki, Irene, et al.
Publicado: (2008)

Characteristics of the population eligible for and receiving publicly funded bariatric surgery in Canada
por: Padwal, Raj S, et al.
Publicado: (2012)

Weight loss maintenance after bariatric surgery
por: Cho, Young-Hye, et al.
Publicado: (2023)

Zoledronate in the prevention of Paget’s (ZiPP): protocol for a randomised trial of genetic testing and targeted zoledronic acid therapy to prevent SQSTM1-mediated Paget’s disease of bone
por: Cronin, Owen, et al.
Publicado: (2019)

Weight Loss Results and Compliance with Follow-up after Bariatric Surgery
por: Reiber, Beata M. M., et al.
Publicado: (2021)

Effect of Zoledronic Acid on Bone Mineral Density in Men with Prostate Cancer Receiving Gonadotropin-Releasing Hormone Analog
por: Kapoor, Anoop, et al.
Publicado: (2011)

Weight Loss Effect of GLP-1 RAs With Endoscopic Bariatric Therapy and Bariatric Surgeries
por: Imam, Ahmad, et al.
Publicado: (2023)

Zoledronic acid in the management of metastatic bone disease
por: Polascik, Thomas J, et al.
Publicado: (2008)

Role of zoledronic acid in oncolytic virotherapy: Promotion of antitumor effect and prevention of bone destruction
por: Yamakawa, Yasuaki, et al.
Publicado: (2017)

Metabolic Bone Disease in the Bariatric Surgery Patient
por: Williams, Susan E.
Publicado: (2011)

The development of machine learning in bariatric surgery
por: Enodien, Bassey, et al.
Publicado: (2023)

Cryoablation combined with zoledronic acid in comparison with cryoablation and zoledronic acid alone in the treatment of painful bone metastases
por: LI, FENQIANG, et al.
Publicado: (2014)

Weight Loss Prediction after Metabolic and Bariatric Surgery
por: Park, Ji Yeon
Publicado: (2023)

Mechanisms of bariatric surgery for weight loss and diabetes remission
por: Yin, Mengsha, et al.
Publicado: (2023)

Rate and Determinants of Excessive Fat-Free Mass Loss After Bariatric Surgery
por: Nuijten, Malou A. H., et al.
Publicado: (2020)

Role of zoledronic acid in the prevention and treatment of osteoporosis
por: Räkel, Agnès, et al.
Publicado: (2011)

Zoledronic acid infusion for prevention and treatment of osteoporosis
por: Sunyecz, John A
Publicado: (2010)

Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving "metronomic" zoledronic acid
por: Zhao, Xinmin, et al.
Publicado: (2011)

Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases
por: Ikesue, Hiroaki, et al.
Publicado: (2021)

Zoledronic acid prevents pagetic-like lesions and accelerated bone loss in the p62(P394L) mouse model of Paget's disease
por: Daroszewska, Anna, et al.
Publicado: (2018)

Zoledronic acid protects from local and systemic bone loss in tumor necrosis factor-mediated arthritis
por: Redlich, K, et al.
Publicado: (2004)

Preventing Wernicke Encephalopathy After Bariatric Surgery
por: Oudman, Erik, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_1l5pm80v4ibqhhe97ko43ga2oq